Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Emerging Infectious Diseases|July 1, 2021
Predictors of Nonseroconversion after SARS-CoV-2 InfectionWeimin Liu, Ronnie M Russell, Frederic Bibollet-Ruche, et al.
Cell|May 18, 2024
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humansWilton B Williams, S Munir Alam, Gilad Ofek, et al.
Annals of Internal Medicine|November 28, 2022
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment TrialGail E Potter, Tyler Bonnett, Kevin Rubenstein, et al.
JAMA|December 18, 2024
2024 Update of the RECOVER-Adult Long COVID Research IndexLinda N Geng, Kristine M Erlandson, Mady Hornig, et al.
JAMA Network Open|September 25, 2025
Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult CohortLeora I Horwitz, Jacqueline H Becker, Weixing Huang, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
Annals of Internal Medicine|July 28, 2025
Social Determinants of Health and Risk for Long COVID in the U.S. RECOVER-Adult CohortCandace H Feldman, Leah Santacroce, Ingrid V Bassett, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Pageof 2